[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 2 of about 2
1. Manchana T, Triratanachat S, Sirisabya N, Vasuratna A, Termrungruanglert W, Tresukosol D: Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer. Gynecol Oncol; 2006 Mar;100(3):556-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer.
  • OBJECTIVES: To evaluate the prevalence of cyclooxygenase-2 (COX-2), correlation with various clinicopathologic factors and prognostic significance of COX-2 in stage IB cervical cancer patients.
  • METHODS: 89 paraffin-embedded specimens of patients with stage IB cervical cancer underwent radical hysterectomy and pelvic lymphadenectomy at King Chulalongkorn Memorial Hospital during 1 January 1997-31 December 2002 and were stained with polyclonal goat antiserum against COX-2 using immunohistochemical method.
  • RESULTS: The prevalence of positive COX-2 expression in stage IB cervical cancer in this study was 49.4%.
  • Positive COX-2 expression in cervical adenocarcinoma was higher than squamous cell carcinoma (86.7% versus 40.6%, P < 0.05) and significantly expressed when lymph node metastasis was presented (100% versus 46.4%, P < 0.05).
  • CONCLUSIONS: Strong correlation was found in cervical adenocarcinoma and lymph node metastasis.
  • However, COX-2 expression failed to demonstrate as a significant prognostic factor in stage IB cervical cancer.
  • [MeSH-major] Cyclooxygenase 2 / biosynthesis. Uterine Cervical Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Humans. Immunohistochemistry. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging


Advertisement
2. Bristow RE, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL 2nd, Peeler ST: Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier: a cost-effectiveness analysis. Gynecol Oncol; 2007 Mar;104(3):739-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the cost-effectiveness of an adhesion prevention strategy compared to routine care, in which no adhesion prevention measures are taken, through a decision analysis model in the clinical setting of patients undergoing radical hysterectomy and pelvic lymphadenectomy for Stage IB cervical cancer.
  • METHODS: A decision analysis model compared two strategies to manage the risk of adhesion-related morbidity following radical hysterectomy for Stage IB cervical cancer:.
  • CONCLUSIONS: Under a conservative set of clinical and economic assumptions, an adhesion prevention strategy utilizing a HA-CMC barrier in patients undergoing radical hysterectomy for Stage IB cervical cancer is cost-effective from both the perspective of society as a whole and that of a third party payer.
  • [MeSH-major] Carboxymethylcellulose Sodium / administration & dosage. Hyaluronic Acid / administration & dosage. Hysterectomy / adverse effects. Intestinal Obstruction / prevention & control. Models, Economic. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Cost-Benefit Analysis. Decision Support Techniques. Drug Costs. Female. Humans. Insurance, Health, Reimbursement. Intestine, Small. Tissue Adhesions / complications. Tissue Adhesions / prevention & control






Advertisement